GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hansa Biopharma AB (OTCPK:HNSBF) » Definitions » Accumulated other comprehensive income (loss)

Hansa Biopharma AB (Hansa Biopharma AB) Accumulated other comprehensive income (loss) : $0.00 Mil (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Hansa Biopharma AB Accumulated other comprehensive income (loss)?

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings. Hansa Biopharma AB's Accumulated other comprehensive income (loss) for the quarter that ended in Mar. 2024 was $0.00 Mil.

Hansa Biopharma AB Accumulated other comprehensive income (loss) Historical Data

The historical data trend for Hansa Biopharma AB's Accumulated other comprehensive income (loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hansa Biopharma AB Accumulated other comprehensive income (loss) Chart

Hansa Biopharma AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Accumulated other comprehensive income (loss)
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Hansa Biopharma AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Accumulated other comprehensive income (loss) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Hansa Biopharma AB Accumulated other comprehensive income (loss) Calculation

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings.

Hansa Biopharma AB Accumulated other comprehensive income (loss) Related Terms

Thank you for viewing the detailed overview of Hansa Biopharma AB's Accumulated other comprehensive income (loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Hansa Biopharma AB (Hansa Biopharma AB) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hansa Biopharma AB (OTCPK:HNSBF) » Definitions » Accumulated other comprehensive income (loss)
Comparable Companies
OSTO:IBT B OSTO:FLUO OSTO:XSPRAY OSTO:EGTX OSTO:BINV OSTO:VICO OSTO:ONCO OSTO:CANTA OSTO:XBRANE XSAT:CURAS OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
HNSA:Sweden 0RC7:UK 24H:Germany
Address
Scheelevagen 22, Lund, SWE, 223 63
Website
https://www.hansabiopharma.com
Hansa Biopharma AB is a biopharmaceutical company that develops immunomodulatory treatments for enabling transplantations and rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection, and cancer. The company's product candidate, imlifidase, is an antibody-cleaving enzyme being developed to enable kidney transplantation in sensitized patients and further developed for use in other organ and tissue transplantation as well as acute autoimmune indications. It operates in Sweden, other European countries, and the U.S. The group generates the majority of its revenue from product sales.